<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463134</url>
  </required_header>
  <id_info>
    <org_study_id>2020.123</org_study_id>
    <nct_id>NCT04463134</nct_id>
  </id_info>
  <brief_title>An Observational Study on Patients With NTM Pulmonary Disease</brief_title>
  <official_title>A Prospective Observational Study of Parameters Related to the Clinical Outcomes of NTM Pulmonary Disease in Prince of Wales Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-tuberculous mycobacterial (NTM) infection is becoming more and more common, especially
      causing pulmonary diseases in those elderly or the immunocompromised. The diagnosis,
      treatment and monitoring of NTM pulmonary disease(NTMPD) are not updated and real life
      management if also challenging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-tuberculous mycobacteria (NTM) are a large group of ubiquitous microorganisms in the
      natural environment as well as household water systems . Over 180 different species have been
      identified but only 32 are reported to cause diseases in human or animals. NTM infection can
      affect the lung, skin and soft tissue, lymph node or cause disseminated diseases in the
      immunocompromised. NTM pulmonary diseases are the most important disease entity, accounting
      for 75-94% of all clinically important NTM cases.

      The predominant species and their pathogenicity vary in different countries. While
      Mycobacterium avium-intracellulare complex (MAC) is most prevalent in the USA, Canada,
      Australia, Japan, Taiwan and Hong Kong, M. abscessus complex is more common in Singapore and
      M. Kansasii in European counties, respectively. Recently reports showed an increasing trend
      in importance of NTM PD in a few countries.

      NTM can cause chronic and debilitating pulmonary disease with increased morbidity and even
      mortality. Healthy individuals can be affected though many have underlying structural lung
      diseases or immunodeficient conditions. Patients usually present with nonspecific symptoms,
      including productive cough, dyspnea, hemoptysis, fever, weight loss and malaise. Therefore,
      the diagnosis of NTM pulmonary disease (NTMPD) is challenging requiring comprehensive
      clinical, microbiological and radiological data according to in the American Thoracic Society
      and Infectious Diseases Society of America (ATS/IDSA) 2007 guidelines. Treatment of NTMPD is
      also a difficult decision because some remain stable for a long period without treatment
      while the others progress to severe and even fatal diseases. A prolonged course of antibiotic
      involving multiple agents with potential adverse effects is needed but a cure cannot be
      guaranteed. Moreover, the treatment regimens might be different from those recommended by the
      international guidelines after balancing multiple factors, including patients' comorbidities,
      disease severity, and the species and antimicrobial susceptibility of the causative organism.
      Therefore, whom to treat, when to start and how to treat is a clinical dilemma.
      Epidemiological data of NTM remains unclear although an increase in prevalence and incidence
      are consistently observed globally. It is not a notifiable disease in most of the countries
      and data mainly comes from sentinel surveillance and microbiological results.

      Local epidemiological data of NTM infection in Hong Kong is largely scarce apart from a small
      study done 25 years ago in 1995. Further local investigation on the epidemiology, disease
      course and clinical practice is needed to optimize their management.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcomes of NTMPD patients with or without treatment in 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical outcomes include stable disease, disease progression, chest infection, death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters that predict the disease progression</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical parameters include demographics and comorbidities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional</measure>
    <time_frame>1 year</time_frame>
    <description>functional capacity of patients including mobility, exercise tolerance, lung function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological parameters that predict disease progression</measure>
    <time_frame>1 year</time_frame>
    <description>species subtypes, smear positivity and drug resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological features that predict disease progression</measure>
    <time_frame>1 year</time_frame>
    <description>Pattern and extent of lung involvement</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Clinical Outcomes</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <description>They will start pharmacological treatment according to guidelines and sensitivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation group</arm_group_label>
    <description>They will not start pharmacological treatment. They will be monitored on symptoms, sputum conversion and radiological progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTM drug treatment</intervention_name>
    <description>NTM drug treatment according to guideline and sensitivity test results</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>pharmacological treatment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults suspected NTMPD followed up in the Prince of Wales Hospital will be recruited
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 or above

          -  Two or more respiratory samples positive for NTM, including sputum, tracheal
             aspirates, bronchial washing, bronchial aspirates, bronchial trap and bronchoalveolar
             lavage or lung biopsy

        Exclusion Criteria:

          -  NTM isolates from extrapulmonary samples

          -  Refused to sign an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015 Mar;36(1):35-41. doi: 10.1016/j.ccm.2014.10.003. Epub 2014 Nov 6. Review.</citation>
    <PMID>25676517</PMID>
  </reference>
  <reference>
    <citation>Gebert MJ, Delgado-Baquerizo M, Oliverio AM, Webster TM, Nichols LM, Honda JR, Chan ED, Adjemian J, Dunn RR, Fierer N. Ecological Analyses of Mycobacteria in Showerhead Biofilms and Their Relevance to Human Health. mBio. 2018 Oct 30;9(5). pii: e01614-18. doi: 10.1128/mBio.01614-18.</citation>
    <PMID>30377276</PMID>
  </reference>
  <reference>
    <citation>Gupta RS, Lo B, Son J. Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera. Front Microbiol. 2018 Feb 13;9:67. doi: 10.3389/fmicb.2018.00067. eCollection 2018. Erratum in: Front Microbiol. 2019 Apr 09;10:714.</citation>
    <PMID>29497402</PMID>
  </reference>
  <reference>
    <citation>Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015 Mar;36(1):91-9. doi: 10.1016/j.ccm.2014.11.002. Epub 2014 Dec 23. Review.</citation>
    <PMID>25676522</PMID>
  </reference>
  <reference>
    <citation>Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014 Mar;6(3):210-20. doi: 10.3978/j.issn.2072-1439.2013.12.24. Review.</citation>
    <PMID>24624285</PMID>
  </reference>
  <reference>
    <citation>Zweijpfenning SMH, Ingen JV, Hoefsloot W. Geographic Distribution of Nontuberculous Mycobacteria Isolated from Clinical Specimens: A Systematic Review. Semin Respir Crit Care Med. 2018 Jun;39(3):336-342. doi: 10.1055/s-0038-1660864. Epub 2018 Aug 2.</citation>
    <PMID>30071548</PMID>
  </reference>
  <reference>
    <citation>Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010 Oct 1;182(7):970-6. doi: 10.1164/rccm.201002-0310OC. Epub 2010 Jun 10.</citation>
    <PMID>20538958</PMID>
  </reference>
  <reference>
    <citation>Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, Mitarai S. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis. 2016 Jun;22(6):1116-7. doi: 10.3201/eid2206.151086.</citation>
    <PMID>27191735</PMID>
  </reference>
  <reference>
    <citation>Kim HO, Lee K, Choi HK, Ha S, Lee SM, Seo GH. Incidence, comorbidities, and treatment patterns of nontuberculous mycobacterial infection in South Korea. Medicine (Baltimore). 2019 Nov;98(45):e17869. doi: 10.1097/MD.0000000000017869.</citation>
    <PMID>31702652</PMID>
  </reference>
  <reference>
    <citation>Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, Ogata H, Kurashima A, Gemma A, Kudoh S. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014 Jan;11(1):1-8. doi: 10.1513/AnnalsATS.201303-067OC.</citation>
    <PMID>24102151</PMID>
  </reference>
  <reference>
    <citation>Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014. Ann Am Thorac Soc. 2016 Nov;13(11):1951-1955.</citation>
    <PMID>27607541</PMID>
  </reference>
  <reference>
    <citation>Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. Review. Erratum in: Am J Respir Crit Care Med. 2007 Apr 1;175(7):744-5. Dosage error in article text.</citation>
    <PMID>17277290</PMID>
  </reference>
  <reference>
    <citation>Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017 Mar 8;49(3). pii: 1600537. doi: 10.1183/13993003.00537-2016. Print 2017 Mar.</citation>
    <PMID>28275170</PMID>
  </reference>
  <reference>
    <citation>Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis. 2017 Feb 1;64(3):301-308. doi: 10.1093/cid/ciw723. Epub 2016 Nov 10. Erratum in: Clin Infect Dis. 2017 May 15;64(10):1469.</citation>
    <PMID>28011609</PMID>
  </reference>
  <reference>
    <citation>Igari H, Yamagishi K, Yamazaki S, Murata S, Yahaba M, Takayanagi S, Kawasaki Y, Taniguchi T. A retrospective observational study of antimicrobial treatment for non-tuberculous mycobacteria disease using a nationwide claims database in Japan. J Infect Chemother. 2020 Apr;26(4):349-352. doi: 10.1016/j.jiac.2019.10.009. Epub 2019 Nov 11.</citation>
    <PMID>31727566</PMID>
  </reference>
  <reference>
    <citation>van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffith DE; NTM-NET. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J. 2017 Feb 15;49(2). pii: 1601855. doi: 10.1183/13993003.01855-2016. Print 2017 Feb.</citation>
    <PMID>28182571</PMID>
  </reference>
  <reference>
    <citation>Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012 Apr 15;185(8):881-6. doi: 10.1164/rccm.201111-2016OC. Epub 2012 Feb 3.</citation>
    <PMID>22312016</PMID>
  </reference>
  <reference>
    <citation>Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, Lipman M, Abubakar I. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect Dis. 2016 May 6;16:195. doi: 10.1186/s12879-016-1521-3.</citation>
    <PMID>27154015</PMID>
  </reference>
  <reference>
    <citation>Thomson R, Donnan E, Konstantinos A. Notification of Nontuberculous Mycobacteria: An Australian Perspective. Ann Am Thorac Soc. 2017 Mar;14(3):318-323. doi: 10.1513/AnnalsATS.201612-994OI.</citation>
    <PMID>28118021</PMID>
  </reference>
  <reference>
    <citation>Ide S, Nakamura S, Yamamoto Y, Kohno Y, Fukuda Y, Ikeda H, Sasaki E, Yanagihara K, Higashiyama Y, Hashiguchi K, Futsuki Y, Inoue Y, Fukushima K, Suyama N, Kohno S. Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. PLoS One. 2015 May 28;10(5):e0128304. doi: 10.1371/journal.pone.0128304. eCollection 2015.</citation>
    <PMID>26020948</PMID>
  </reference>
  <reference>
    <citation>Ding LW, Lai CC, Lee LN, Hsueh PR. Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. Epidemiol Infect. 2006 Oct;134(5):1060-7. Epub 2006 Feb 22.</citation>
    <PMID>16492317</PMID>
  </reference>
  <reference>
    <citation>Park YS, Lee CH, Lee SM, Yang SC, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis. 2010 Aug;14(8):1069-71.</citation>
    <PMID>20626955</PMID>
  </reference>
  <reference>
    <citation>Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016 Apr;45:123-34. doi: 10.1016/j.ijid.2016.03.006. Epub 2016 Mar 11. Review.</citation>
    <PMID>26976549</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>LAI PING LO</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Disease progression, death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

